MDP Stock Overview
Operates as a specialty pharmaceutical company in Canada and the United States.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 4/6 |
Past Performance | 3/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Medexus Pharmaceuticals Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$1.55 |
52 Week High | CA$3.53 |
52 Week Low | CA$1.19 |
Beta | 1.89 |
1 Month Change | -3.13% |
3 Month Change | 0.65% |
1 Year Change | 29.17% |
3 Year Change | -79.28% |
5 Year Change | -67.02% |
Change since IPO | -79.33% |
Recent News & Updates
The Market Doesn't Like What It Sees From Medexus Pharmaceuticals Inc.'s (TSE:MDP) Revenues Yet
Jun 15Here's Why Medexus Pharmaceuticals (TSE:MDP) Has A Meaningful Debt Burden
Apr 25Revenues Working Against Medexus Pharmaceuticals Inc.'s (TSE:MDP) Share Price Following 26% Dive
Mar 03Recent updates
The Market Doesn't Like What It Sees From Medexus Pharmaceuticals Inc.'s (TSE:MDP) Revenues Yet
Jun 15Here's Why Medexus Pharmaceuticals (TSE:MDP) Has A Meaningful Debt Burden
Apr 25Revenues Working Against Medexus Pharmaceuticals Inc.'s (TSE:MDP) Share Price Following 26% Dive
Mar 03Medexus Pharmaceuticals Inc.'s (TSE:MDP) Shares Leap 89% Yet They're Still Not Telling The Full Story
Jan 06Here's Why Medexus Pharmaceuticals (TSE:MDP) Has Caught The Eye Of Investors
Oct 11Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Sep 11Medexus Pharmaceuticals (TSE:MDP) Use Of Debt Could Be Considered Risky
Jan 19Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Sep 22Is Medexus Pharmaceuticals (TSE:MDP) Weighed On By Its Debt Load?
Dec 16Medexus Pharmaceuticals Inc. (TSE:MDP) Analysts Just Cut Their EPS Forecasts Substantially
Aug 21Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Aug 04Medexus Pharmaceuticals Inc. (CVE:MDP): When Will It Breakeven?
May 04The Independent Director of Medexus Pharmaceuticals Inc. (CVE:MDP), Michael Mueller, Just Bought 34% More Shares
Feb 26Shareholder Returns
MDP | CA Pharmaceuticals | CA Market | |
---|---|---|---|
7D | -12.9% | -7.3% | -2.2% |
1Y | 29.2% | 31.1% | 8.1% |
Return vs Industry: MDP underperformed the Canadian Pharmaceuticals industry which returned 31.4% over the past year.
Return vs Market: MDP exceeded the Canadian Market which returned 8% over the past year.
Price Volatility
MDP volatility | |
---|---|
MDP Average Weekly Movement | 7.8% |
Pharmaceuticals Industry Average Movement | 13.4% |
Market Average Movement | 8.3% |
10% most volatile stocks in CA Market | 17.0% |
10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: MDP has not had significant price volatility in the past 3 months.
Volatility Over Time: MDP's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 98 | Ken d'Entremont | www.medexus.com |
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Medexus Pharmaceuticals Inc. Fundamentals Summary
MDP fundamental statistics | |
---|---|
Market cap | CA$37.91m |
Earnings (TTM) | CA$8.08m |
Revenue (TTM) | CA$158.93m |
4.7x
P/E Ratio0.2x
P/S RatioIs MDP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MDP income statement (TTM) | |
---|---|
Revenue | US$115.73m |
Cost of Revenue | US$48.91m |
Gross Profit | US$66.81m |
Other Expenses | US$60.93m |
Earnings | US$5.88m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.24 |
Gross Margin | 57.73% |
Net Profit Margin | 5.08% |
Debt/Equity Ratio | 174.9% |
How did MDP perform over the long term?
See historical performance and comparison